Identification of potential plasma protein biomarkers for feline pancreatic carcinoma by liquid chromatography tandem mass spectrometry

In both humans and cats, pancreatic carcinoma is an aggressive cancer with a grave prognosis. Proteomics techniques have successfully identified several blood‐based biomarkers of human pancreatic neoplasia. Thus, this study aims to investigate whether similar biomarkers can be identified in the plas...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary & comparative oncology 2022-09, Vol.20 (3), p.720-731
Main Authors: Nabeta, Rina, Katselis, George S., Chumala, Paulos, Dickinson, Ryan, Fernandez, Nicole J., Meachem, Melissa D.
Format: Article
Language:English
Subjects:
Animals
Biomarkers
Biomarkers, Tumor
Blood Proteins
Cats
Chromatography, Liquid - methods
Chromatography, Liquid - veterinary
ETV4 protein
felines
gelsolin
Humans
pancreatic carcinoma
Pancreatic Neoplasms
tandem mass spectrometry
Tandem Mass Spectrometry - methods
Tandem Mass Spectrometry - veterinary
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In both humans and cats, pancreatic carcinoma is an aggressive cancer with a grave prognosis. Proteomics techniques have successfully identified several blood‐based biomarkers of human pancreatic neoplasia. Thus, this study aims to investigate whether similar biomarkers can be identified in the plasma of cats with FePAC by using liquid chromatography tandem mass spectrometry (LC–MS/MS). To facilitate evaluation of the low abundance plasma proteome, a human‐based immunodepletion device (MARS‐2) was first validated for use with feline plasma. Marked reduction and/or complete removal of albumin and immunoglobulins was confirmed by analysis of electrophoretograms and mass spectral data. Subsequently, plasma collected from 9 cats with pancreatic carcinoma (FePAC), 10 cats with symptomatic pancreatitis, and 10 healthy control cats was immunodepleted and subjected to LC–MS/MS. Thirty‐seven plasma proteins were found to be differentially expressed (p 2 in fold change analysis). Among these proteins, ETS variant transcription factor 4 (p 
ISSN:1476-5810
1476-5829
DOI:10.1111/vco.12826